Medical Management of Uterine Fibroids-A hope for Fertile Women!

Suresh K
{"title":"Medical Management of Uterine Fibroids-A hope for Fertile Women!","authors":"Suresh K","doi":"10.31579/2578-8965/207","DOIUrl":null,"url":null,"abstract":"Uterine fibroids or Myomas or Leiomyoma of uterus are the most common type of benign tumor of uterus and most common pelvic tumour in women with unclear etiology. Uterine fibroids or Myomas or Leiomyoma of uterus are the most common type of benign tumor of uterus. In India the incidence of fibroids is most common in women of 31- 40 years of age i.e. as more than 1/3 (35%) of them get affected. Recent understanding of etiology suggests increased number of estrogen and Progesterone Receptors, increased COMT gene expression and TGF-B3. Risk factors for developing fibroids are age, early age at menarche, reduced fertility, frequent caffeine consumption, obesity, hypertension, diabetes mellitus, alcohol consumption and previous pelvic inflammatory disease (PID). Rural women are at a much higher risk of uterine fibroids than urban women in India. (37.65% vs.24%) probably due to multiparty at a young age disturbing Estrogen and Progesterone Receptors. Treatment options for symptomatic uterine fibroids include medical, surgical, and radiologically guided interventions. Although curative treatment relies on surgical therapies- either myomectomy or hysterectomy, medical treatments are considered the first-line treatment to preserve fertility and avoid or delay surgery. Medical therapy is in nascent stage in India. Medical treatment must be individualized based on age, signs & symptoms, sustained reduction of the size and sustenance of fertility if desired with minimal side effects. Materials and Methods: This article is based on a literature review on medical therapy being tried on a case the author is managing now. The initial results are encouraging and need to monitor the reduction of the size or volume of the Fibroid in coming months.","PeriodicalId":19413,"journal":{"name":"Obstetrics Gynecology and Reproductive Sciences","volume":"24 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics Gynecology and Reproductive Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2578-8965/207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Uterine fibroids or Myomas or Leiomyoma of uterus are the most common type of benign tumor of uterus and most common pelvic tumour in women with unclear etiology. Uterine fibroids or Myomas or Leiomyoma of uterus are the most common type of benign tumor of uterus. In India the incidence of fibroids is most common in women of 31- 40 years of age i.e. as more than 1/3 (35%) of them get affected. Recent understanding of etiology suggests increased number of estrogen and Progesterone Receptors, increased COMT gene expression and TGF-B3. Risk factors for developing fibroids are age, early age at menarche, reduced fertility, frequent caffeine consumption, obesity, hypertension, diabetes mellitus, alcohol consumption and previous pelvic inflammatory disease (PID). Rural women are at a much higher risk of uterine fibroids than urban women in India. (37.65% vs.24%) probably due to multiparty at a young age disturbing Estrogen and Progesterone Receptors. Treatment options for symptomatic uterine fibroids include medical, surgical, and radiologically guided interventions. Although curative treatment relies on surgical therapies- either myomectomy or hysterectomy, medical treatments are considered the first-line treatment to preserve fertility and avoid or delay surgery. Medical therapy is in nascent stage in India. Medical treatment must be individualized based on age, signs & symptoms, sustained reduction of the size and sustenance of fertility if desired with minimal side effects. Materials and Methods: This article is based on a literature review on medical therapy being tried on a case the author is managing now. The initial results are encouraging and need to monitor the reduction of the size or volume of the Fibroid in coming months.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
子宫肌瘤的医学治疗--生育妇女的希望!
子宫肌瘤或子宫肌瘤或子宫雷肌瘤是最常见的子宫良性肿瘤,也是妇女最常见的盆腔肿瘤,病因不清。子宫肌瘤或子宫肌瘤或子宫亮肌瘤是最常见的子宫良性肿瘤。在印度,子宫肌瘤的发病率在 31-40 岁的女性中最为常见,即超过 1/3(35%)的女性会受到影响。最近对病因的了解表明,雌激素和孕酮受体数量增加,COMT 基因表达和 TGF-B3 增加。罹患子宫肌瘤的风险因素包括年龄、初潮年龄过早、生育能力下降、经常饮用咖啡因、肥胖、高血压、糖尿病、饮酒和曾患盆腔炎(PID)。在印度,农村妇女患子宫肌瘤的风险比城市妇女高得多。(在印度,农村妇女患子宫肌瘤的风险比城市妇女高得多(37.65% 对 24%),这可能是由于年轻时多产扰乱了雌激素和孕激素受体。无症状子宫肌瘤的治疗方法包括药物、手术和放射引导干预。虽然根治性治疗依赖于手术疗法--肌瘤剔除术或子宫切除术,但药物疗法被认为是保留生育能力、避免或推迟手术的一线治疗方法。医学治疗在印度尚处于起步阶段。医学治疗必须根据患者的年龄、体征和症状进行个体化治疗,并在副作用最小的情况下持续缩小肌瘤大小和保持生育能力。材料与方法:本文基于对作者正在治疗的一个病例进行医学治疗的文献综述。初步结果令人鼓舞,需要在未来几个月内监测子宫肌瘤体积的缩小情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Effect of In-vitro Fertilization Procedures on Alpha-fetoprotein Levels in Second Trimester Screening for Fetal Defects Medical Management of Uterine Fibroids-A hope for Fertile Women! Evaluation of Antithrombin-III Activity and Platelet Count in Pregnancy-Induced Hypertension among Pregnant Women attending Antenatal care in a Tertiary Health Facility in Southeast, Nigeria Male Infertility – An Overview of Management Comparison of Two Types of Endometrial Scratch before Embryo Transfer and Patient-Reported Pain Scores: A Prospective Randomized Pilot Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1